BioStock: Cyxone announces expanded plans for Rabeximod

The Swedish biotech company Cyxone recently announced expanded plans for the development of their drug candidate Rabeximod. Four new patent applications were filed earlier this year greatly extending the potential for market exclusivity. This has led to a revision of the Rabeximod development plan. The number of possible applications and therefore the value of Rabeximod has increased significantly. The Covid-19 global pandemic continues with an imminent and immense need for better treatments where Cyxone believes that Rabeximod can make a difference. Cyxone will conduct a phase II study with Rabeximod in moderate patients with Covid-19, likely to start in the fourth quarter of 2020.

Read the full article about Cyxone at

This is a pressrelease from BioStock - Connecting Innovation & Capital

About Us

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50,


Quick facts

BioStock: Cyxone announces expanded plans for Rabeximod
Tweet this